Astonea Labs Ltd

Astonea Labs Limited: Trading Window shall remain closed with effect from Thursday, October 1, 2026 until 48 hours after the declaration of the Unaudited Financial Results (Standalone & Consolidated) for the half-year ending September 30, 2026.

Clarification on PDF result submission

• HY and FY 2025 standalone results were submitted in XBRL mode.
• PDF version for HY2025 could not be uploaded due to inadvertent omission.
• Requisite PDF of HY standalone results submitted for the Exchange's record.

Regulatory filings corrections

• Standalone FY2025 results were submitted in XBRL mode; PDF version not uploaded due to inadvertent omission.
• Company is submitting the PDF standalone results to BSE for records and action.
• Declaration under Regulation 33(3) was already submitted in PDF; portal query remained open.
• GSTIN and CIN details provided; declaration re-submitted with clarifications to complete regulatory compliance.
• The company requests BSE to cognize submission and update exchange records.

Acquisition details

• Target: ASTONEA LABS LIMITED, listed on BSE Limited.
• Acquirer and PAC: Ashish Gulati.
• Acquirer promoter status: Yes, promoter of the company.
• Pre-acquisition holding: 74,42,970 shares (70.81%).
• Acquisition: 14,000 voting rights acquired (0.13%).
• Post-acquisition holding: 74,56,970 shares (70.94%).
• Mode of acquisition: Open Market.
• Date of acquisition: 15 Sep 2026 to 16 Sep 2026.
• Equity share capital before/after: 1,05,11,000 shares (no change).
• Salient features: Not Applicable.

Insider-trading disclosure

• Promoter Group member Ashish Gulati disclosed acquisition of 14,000 equity shares on Sep 15-16, 2026 via Form C.
• Submission made under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Disclosure details

• Promoter Ashish Gulati, a member of promoter group, acquired 14,000 equity shares of Astonea Labs.
• Acquisition occurred on September 15-16, 2026.
• Disclosure filed under Regulation 29(1) SEBI (SAST) Regulations, 2011.
• Filing submitted to BSE for information and records.

Appointment of Internal Auditor

• Board approved appointment of Mr. Chander Shekhar as Internal Auditor for FY 2026-27.
• Appointment recommended by Audit Committee under Section 138 of the Companies Act, 2013.
• Date of appointment: 09 September 2026.
• Term of appointment: Financial Year 2026-27.
• Name and affiliation: Mr. Chander Shekhar, CA, Chander Shekhar & Associates (FRN 020828N).
• Relation with the company: Not related to Directors or KMP.
• Regulatory compliance: approved under Regulation 30 and Annexure-A.
• Brief profile: Chartered Accountant with extensive audit and financial reporting experience.

Key Decisions

• Cost Audit Report for FY2025-26 taken on record; no adverse remarks.
• Appointed Internal Auditor for FY2026-27: Mr. Chander Shekhar (CA) of Chander Shekhar & Associates; effective 09 Sep 2026.
• Approved incorporation of Longevity Science Private Limited subsidiary; Company to hold ≥51% voting power; name correction in process.
• Approved ODI: initial USD 10,000 investment in Astonea LLC, USA; 100% ownership.
• Terminated agreements with Astonea One Private Limited: supply/manufacture and distribution/brand license; termination for immediate effect.

Director re-appointment

• Ms. Pooja Singh was re-appointed as Director at the AGM on 21 August 2026.
• She was liable to retire by rotation and offered for re-appointment, which was approved.
• Term: re-appointment as Director liable to retirement by rotation under Companies Act 2013 and AoA.
• Brief profile: B.Pharm with over eight years in QA, regulatory affairs, and pharma operations.
• Current role: heads the Drug Regulatory Affairs Department since 2021.
• Expertise: Quality Assurance, Regulatory Compliance, DRA, and pharmaceutical operations.
• Relationship: not related to any Director, Manager or KMP.
• Directorships in listed entities: NIL; CSR Committee: Member of CSR Committee of Astonea Labs.
• No listed-entity resignations disclosed in last three years.
• Shareholding in the company: NIL.